Randomized Pilot Trial on Optimal Treatment Strategy, Myocardial Changes, and Prognosis of Patients with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA)

Myocardial infarction with nonobstructive coronary arteries (MINOCA) remains an unresolved challenge. Many different diagnostic approaches are often required to diagnose, confirm, and evaluate MINOCA. The prevalence can be as high as 13% of all acute myocardial infarction patients, indicating that t...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of medicine Vol. 135; no. 1; pp. 103 - 109
Main Authors: Serpytis, Rokas, Majauskiene, Egle, Navickas, Petras, Lizaitis, Mindaugas, Glaveckaite, Sigita, Rucinskas, Kestutis, Petrulioniene, Zaneta, Valeviciene, Nomeda, Samalavicius, Robertas Stasys, Berukstis, Andrius, Baranauskas, Arvydas, Gargalskaite, Urte, Laucevicius, Aleksandras, Chen, Qin M., Alpert, Joseph S., Serpytis, Pranas
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01-01-2022
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myocardial infarction with nonobstructive coronary arteries (MINOCA) remains an unresolved challenge. Many different diagnostic approaches are often required to diagnose, confirm, and evaluate MINOCA. The prevalence can be as high as 13% of all acute myocardial infarction patients, indicating that this condition is not rare. At this time, there have been no completed randomized clinical trials involving MINOCA patients, and a better understanding of the mechanisms and management of these patients is important. This exploratory analysis seeks to find possible etiologic factors, the value of novel biomarkers, and the effect of different treatment strategies in patients with MINOCA. This prospective randomized pilot trial will include 150 patients with MINOCA. A thorough clinical, laboratory, and imaging evaluation will be performed, including novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing). The duration of the enrollment is 18 months, and duration of the follow-up is 12 months from the enrollment of the first patient. The trial is registered under www.clinicaltrials.gov: NCT04538924. The study is currently recruiting participants. Because MINOCA is not a benign disease, the results of the current investigation could inform future diagnostic and therapeutic strategies and enhance the understanding of MINOCA patients.
ISSN:0002-9343
1555-7162
DOI:10.1016/j.amjmed.2021.08.023